臨床外科76巻2号

2021年02月発行

特集 外科医のための—悪性腫瘍補助療法のすべて 各論

消化管GISTの術前術後補助療法

著者： 山下晃平¹ 岩槻政晃¹ 古閑悠輝¹ 松本千尋¹ 森永剛司¹ 中村健一¹ 岩上志朗¹ 吉田直矢¹ 馬場秀夫¹

所属機関： ¹熊本大学大学院生命科学研究部消化器外科学

ページ範囲：P.222 - P.226

【ポイント】
◆拡大手術が必要あるいは手術リスクの高いGISTでは，術前補助療法により完全切除率の向上や手術の低侵襲化が期待できる．
◆高リスクまたは偽被膜損傷などを呈するclinically malignantのGISTでは，術後3年間のイマチニブ療法が強く推奨される．
◆術後補助療法の遵守率の向上とともに，適切な患者選択のためのバイオマーカーの開発がGISTの予後向上につながる．

参考文献

1）Eisenberg BL, Harris J, Blanke CD, et al：Phase Ⅱ trial of neoadjuvant/adjuvant imatinib mesylate（IM）for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor（GIST）：early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99：42-47, 2009

2）Wang D, Zhang Q, Blanke CD, et al：Phase Ⅱ trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors：long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 19：1074-1080, 2012

3）Kurokawa Y, Yang HK, Cho H, et al：Phase Ⅱ study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117：25-32, 2017

4）Rutkowski P, Gronchi A, Hohenberger P, et al：Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors（GIST）：the EORTC STBSG experience. Ann Surg Oncol 20：2937-2943, 2013

5）Tielen R, Verhoef C, van Coevorden F, et al：Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol 39：150-155, 2013

6）DeMatteo RP, Ballman KV, Antonescu CR, et al：Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor：ACOSOG Z9000（Alliance）intergroup phase 2 trial. Ann Surg 258：422-429, 2013

7）Dematteo RP, Ballman KV, Antonescu CR, et al：Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour：a randomised, double-blind, placebo-controlled trial. Lancet 373：1097-1104, 2009

8）Corless CL, Ballman KV, Antonescu CR, et al：Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor：the ACOSOG Z9001 trial. J Clin Oncol 32：1563-1570, 2014

9）Casali PG, Le Cesne A, Poveda Velasco A, et al：Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant：A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33：4276-4283, 2015

10）Joensuu H, Eriksson M, Sundby Hall K, et al：One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor：a randomized trial. JAMA 307：1265-1272, 2012

11）Joensuu H, Eriksson M, Sundby Hall K, et al：Adjuvant Imatinib for High-Risk GI Stromal Tumor：Analysis of a Randomized Trial. J Clin Oncol 34：244-250, 2016

12）Joensuu H, Eriksson M, Sundby Hall K, et al：Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors：An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol 6：1241-1246, 2020

13）Raut CP, Espat NJ, Maki RG, et al：Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate-or High-Risk Primary Gastrointestinal Stromal Tumor：The PERSIST-5 Clinical Trial. JAMA Oncol 4：e184060, 2018

14）Nishida T, Sakai Y, Takagi M, et al：Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world. Gastric Cancer 23：118-125, 2020

15）Koga Y, Iwatsuki M, Yamashita K, et al：The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer 22：1100-1108, 2019